Inherited disorders of voltage-gated sodium channels

Journal of Clinical Investigation

Volumn 115, Issue 8, 2005, Pages 1990-1999

  George Jr , Alfred L ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VOLTAGE GATED SODIUM CHANNEL;

DISEASE SEVERITY; EPILEPSY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEART ARRHYTHMIA; HUMAN; MYOPATHY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; GENETIC DISEASES, INBORN; HUMANS; ION CHANNEL GATING; ION TRANSPORT; SODIUM; SODIUM CHANNELS;

EID: 23644433670     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI25505     Document Type: Review

References (160)

1. Catterall, W.A. 1992. Cellular and molecular biology of voltage-gated sodium channels [review]. Physiol. Rev. 72(Suppl. 4):S15-S48.
2. Catterall, W.A. 2000. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 26:13-25.
3. Whitaker, W.R., et al. 2000. Distribution of voltage-gated sodium channel alpha-subunit and beta-subunit mRNAs in human hippocampal formation, cortex, and cerebellum. J. Comp. Neurol. 422:123-139.
4. Trimmer, J.S., et al. 1989. Primary structure and functional expression of a mammalian skeletal muscle sodium channel. Neuron. 3:33-49.
5. George, A.L., Komisarof, J., Kallen, R.G., and Barchi, R.L. 1992. Primary structure of the adult human skeletal muscle voltage-dependent sodium channel. Ann. Neurol. 31:131-137.
6. + channel isoform. Proc. Natl. Acad. Sci. U. S. A. 86:8170-8174.
7. Gellens, M.E., et al. 1992. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc. Natl. Acad. Sci. U. S. A. 89:554-558.
8. Maier, S.K., et al. 2003. An unexpected requirement for brain-type sodium channels for control of heart rate in the mouse sinoatrial node. Proc. Natl. Acad. Sci. U. S. A. 100:3507-3512.
9. Maier, S.K.G., et al. 2002. An unexpected role for brain-type sodium channels in coupling of cell surface depolarization to contraction in the heart. Proc. Natl. Acad. Sci. U. S. A. 99:4073-4078.
10. Stühmer, W., et al. 1989, Structural parts involved in activation and inactivation of the sodium channel Nature. 339:597-603.
11. Yang, N.B., George, A.L., Jr., and Horn, R. 1996. Molecular basis of charge movement in voltage-gated sodium channels. Neuron. 16:113-122.
12. Ren, D., et al. 2001. A prokaryotic voltage-gated sodium channel. Science. 294:2372-2375.
13. Hodgkin, A.L., and Huxley, A.F. 1952. Currents carried by sodium and potassium ion through the membrane of the giant axon of Loligo. J. Physiol. 116:449-472.
14. + channels must deactivate to recover from inactivation. Neuron. 12:819-829.
15. Vilin, Y.Y., and Ruben, P.C. 2001. Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. Cell Biochem. Biophys. 35:171-190.
16. Cannon, S.C., and George, A.L. 2002. Pathophysiology of myotonia and periodic paralysis. In Diseases of the nervous system: clinical neuroscience and therapeutic principles. A.K. Asbury, G.M. Mckhann, W.I. McDonald, P.J. Goadsby, and J.C. McArthur, editors. Cambridge University Press. Cambridge, United Kingdom. 1183-1206.
17. Griggs, R.C. 1977. The myotonic disorders and the periodic paralyses. Adv. Neurol. 17:143-159.
18. Streib, E.W. 1987. Differential diagnosis of myotonic syndromes. Muscle Nerve. 10:603-615.
19. Rüdel, R., Ricker, K., and Lehmann-Horn, F. 1993. Genotype-phenotype correlations in human skeletal muscle sodium channel diseases. Arch. Neurol. 50:1241-1248.
20. Ptacek, L.J., et al. 1991. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 67:1021-1027.
21. Rüdel, R., and Lehmann-Horn, F. 1985. Membrane changes in cells from myotonia patients. Physiol. Rev. 65:310-356.
22. Fontaine, B., et al. 1990, Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha subunit gene. Science. 250:1000-1002.
23. Ptacek, L.J., et al. 1991. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium channel gene locus. Am. J. Hum. Genet. 49:851-854.
24. Ebers, G.C., et al. 1991. Paramyotonia congenita and non-myotonic hyperkalemic periodic paralysis are linked to the adult muscle sodium channel gene. Ann. Neurol. 30:810-816.
25. + channel α-subunit in hyperkalemic periodic paralysis. Nature. 354:387-389.
26. McClatchey, A.I., et al. 1992. Temperature-sensitive mutations in the III-IV cytoplasmic loop region of the skeletal muscle sodium channel gene in paramyotonia congenita. Cell. 68:769-774.
27. Ptacek, L.J., et al. 1992. Mutations in an S4 segment of the adult skeletal muscle sodium channel gene cause paramyotonia congenita. Neuron. 8:891-897.
28. Ptacek., L.J., et al. 1993. Sodium channel mutations in paramyotonia congenita and hyperkalemic periodic paralysis. Ann. Neurol. 33:300-307.
29. Ptacek, L.J., et al. 1994. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology. 44:1500-1503.
30. Lerche, H., et al. 1993. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III/IV linker. J. Physiol. 470:13-22.
31. + channel mutation in adult human skeletal muscle. Ann. Neurol. 39:599-608.
32. Ricker, K., Moxley, R.T., III, Heine, R., and Lehmann-Horn, F. 1994. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch. Neurol. 51:1095-1102.
33. Miller, T.M., et al. 2004. Correlating phenotype and genotype in the periodic paralyses. Neurology. 63:1647-1655.
34. Vita, G.M., et al. 1995. Masseter muscle rigidity associated with glycine-1306 to alanine mutation in the adult muscle sodium channel α-subunit gene. Anesthesiology. 82:1097-1103.
35. Bendahhou, S., et al. 2000. A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation. J. Clin. Invest. 106:431-438.
36. Tsujino, A., et al. 2003. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc. Natl. Acad. Sci. U. S. A. 100:7377-7382.
37. Cannon, S.C., Brown, R.H., and Corey, D.P. 1991. A sodium channel defect in hyperkalemic periodic paralysis: potassium induced failure of inactivation. Neuron. 6:619-626.
38. Cannon, S.C., and Strittmatter, S.M. 1993. Functional expression of sodium channel mutations identified in families with periodic paralysis. Neuron. 10:317-326.
39. Lehmann-Horn, F., et al. 1983. Two cases of adynamia episodica hereditaria: in vitro investigation of muscle cell membrane and contraction parameters. Muscle Nerve. 6:113-121.
40. Rüdel, R., Lehmann-Horn, F., Ricker, K., and Kuther, G. 1984. Hypokalemic periodic paralysis: in vitro investigation of muscle fiber membrane parameters. Muscle Nerve. 7:110-120.
41. Cummins, T.R., and Sigworth, F.J. 1996. Impaired slow inactivation in mutant sodium channels. Biophys. J. 71:227-236.
42. + sodium channel inactivation must be disrupted to evoke prolonged depolarization-induced paralysis. Biophys. J. 66:542-545.
43. Yang, N., et al. 1994. Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. Proc. Natl. Acad. Sci. U. S. A. 91:12785-12789.
44. + current in paramyotonia congenita muscle. Brain. 122:1085-1092.
45. +-aggravated myotonia: destabilization of the inactivated state of the human muscle Na+ channel by the V1589M mutation. J. Physiol. 478:395-402.
46. Mitrovic, N., et al. 1995. Different effects on gating of three myotonia-causing mutations in the inactivation gate of the human muscle sodium channel. J. Physiol. 487:107-114.
47. Hayward, L.J., Brown, R.H., Jr., and Cannon, S.C. 1996. Inactivation defects caused by myotonia-associated mutations in the sodium channel III-IV linker. J. Gen. Physiol. 107:559-576.
48. Cannon, S.C. 1997. From mutation to myotonia in sodium channel disorders. Neuromuscul. Disord. 7:241-249.
49. Adrian, R.H., and Bryant, S.H. 1974. On the repetitive discharge in myotonic muscle fibres. J. Physiol. 240:505-515.
50. Moxley, R.T., III. 2000. Channelopathies. Curr. Treat. Options Neurol. 2:31-47.
51. Meola, G., and Sansone, V. 2000. Therapy in myotonic disorders and in muscle channelopathies [review]. Neurol. Sci. 21(Suppl. 5):S953-S961.
52. Jackson, C.E., Barohn, R.J., and Ptacek, L.J. 1994. Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy. Muscle Nerve. 17:763-768.
53. Kwiecinski, H., Ryniewicz, B., and Ostrzycki, A. 1992. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol. Scand. 86:371-375.
54. + channel. J. Physiol. 537:701-714.
55. Rosenfeld, J., Sloan-Brown, K., and George, A.L., Jr. 1997. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann. Neurol. 42:811-814.
56. Desaphy, J.F., De Luca, A., Didonna, M.P., George, A.L., and Conte, C.D. 2003. Different flecainide sensitivity of hNaV1.4 channels and myotonic mutants explained by state-dependent block. J. Physiol. 554:321-334.
57. Wang, Q., et al. 1995. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 80:805-811.
58. Wang, Q., et al. 1995. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum. Mol. Genet. 4:1603-1607.
59. Chen, Q., et al. 1998, Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 392:293-296.
60. Schott, J.J., et al. 1999. Cardiac conduction defects associate with mutations in SCN5A. Nat. Genet. 23:20-21.
61. Tan, H.L., et al. 2001. A sodium-channel mutation causes isolated cardiac conduction disease. Nature. 409:1043-1047.
62. Wang, D.W., Viswanathan, P.C., Balser, J.R., George, A.L., Jr., and Benson, D.W. 2002. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation. 105:341-346.
63. + channel mutation causing both long-QT and Brugada syndromes. Circ. Res. 85:1206-1213.
64. McNair, W.P., et al. 2004. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 110:2163-2167.
65. Grant, A.O., et al. 2002. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J. Clin. Invest. 110:1201-1209. doi:10.1172/JCI200215570.
66. Makita, N., et al. 2002. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation. 106:1269-1274.
67. Schwartz, P.J., et al. 2000. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N. Engl. J. Med. 343:262-267.
68. Ackerman, M.J., et al. 2001. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA. 286:2264-2269.
69. Splawski, I., et al. 2002. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science. 297:1333-1336.
70. Keating, M.T. 1996. The long QT syndrome. A review of recent molecular genetic and physiologic discoveries [review]. Medicine (Baltimore). 75:1-5.
71. Vincent, G.M. 1998. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu. Rev. Med. 49:263-274.
72. Curran, M.E., et al. 1995. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 80:795-803.
73. Wang, Q., et al. 1996. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. 12:17-23.
74. Schwartz, P.J., et al. 2001. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 103:89-95.
75. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 92:3381-3386.
76. Akai, J., et al. 2000. A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. FEBS Lett. 479:29-34.
77. Vatta, M., et al. 2002. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum. Mol. Genet. 11:337-345.
78. Sangwatanaroj, S., Yanatasneejit, P., Sunsaneewitayakul, B., and Sitthisook, S. 2002. Linkage analyses and SCN5A mutations screening in five sudden unexplained death syndrome (Lai-tai) families. J. Med. Assoc. Thai. 85(Suppl. 1):S54-S61.
79. Brugada, J., and Brugada, P. 1997. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J. Cardiovasc. Electrophysiol. 8:325-331.
80. Brugada, R., et al. 2000. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 101:510-515.
81. Baron, R.C., et al. 1983. Sudden death among Southeast Asian refugees. An unexplained nocturnal phenomenon JAMA. 250:2947-2951.
82. Nademanee, K., et al. 1997. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 96:2595-2600.
83. Sangwatanaroj, S., Ngamchareon, C., and Prechawat, S. 2001. Pattern of inheritance in three sudden unexplained death syndrome ("Lai-tai") families. J. Med. Assoc. Thai. 84(Suppl. 1):S443-S451.
84. Groenewegen, W.A., et al. 2003. A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. Circ. Res. 92:14-22.
85. Benson, D.W., et al. 2003. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest. 112:1019-1028. doi:10.1172/JCI200318062.
86. Lupoglazoff, J.M., et al. 2001. Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block. Circ. Res. 89:E16-E21.
87. Chang, C.C., et al. 2004. A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia. Cardiovasc. Res. 64:268-278.
88. Kyndt, F., et al. 2001. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 104:3081-3086.
89. Olson, T.M., et al. 2005. Sodium channel mutations and susceptibility co heart failure and atrial fibrillation JAMA. 293:447-454.
90. Bennett, P.B., Yazawa, K., Makita, N., and George, A.L., Jr. 1995. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 376:683-685.
91. + channel-linked long-QT syndrome. Circ. Res. 78:916-924.
92. + channel mutations in the congenital long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 93:13200-13205.
93. Kambouris, N.G., et al. 1998. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Circulation. 97:640-644.
94. + channel. Circ. Res. 88:740-745.
95. Clancy, C.E., and Rudy, Y. 1999. Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature. 400:566-569.
96. Antzelevitch, C., Yan, G.X., and Shimizu, W. 1999. Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome [review]. J. Electrocardiol. 32(Suppl.):158-165.
97. Nuyens, D., et al. 2001. Abrupt rate acceletations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat. Med. 7:1021-1027.
98. Yan, G.X., and Antzelevitch, C. 1999. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated wich ST-segment elevation. Circulation. 100:1660-1666.
99. Antzelevitch, C. 1999. Ion channels and ventricular arrhythmias: cellular and ionic mechanisms underlying the Brugada syndrome. Curr. Opin. Cardiol. 14:274-279.
100. Schulze-Bahr, E., et al. 2003. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum. Mutat. 21:651-652.
101. Baroudi, G., Acharfi, S., Larouche, C., and Chahine, M. 2002. Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. Circ. Res. 90:E11-E16.
102. Baroudi, G., et al. 2001. Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). Circ. Res. 88:E78-E83.
103. Baroudi, G., Napolitano, C., Priori, S.G., Del Bufalo, A., and Chahine, M. 2004. Loss of function associated with novel mutations of the SCN5A gene in patients with Brugada syndrome. Can. J. Cardiol. 20:425-430.
104. Valdivia, C.R., et al. 2004. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc. Res. 62:53-62.
105. Dumaine, R., et al. 1999. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ. Res. 85:803-809.
106. + channel intermediate inactivation in Brugada syndrome. Circ. Res. 87:E37-E43.
107. Rook, M.B., et al. 1999. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc. Res. 44:507-517.
108. + channel mutation leading to loss of function and non-progressive cardiac conduction defects. J. Mol. Cell. Cardiol. 35:549-557.
109. Probst, V., et al. 2003. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease. J. Am. Coll. Cardiol. 41:643-652.
110. Clancy, C.E., and Rudy, Y. 2002. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation. 105:1208-1213.
111. Bezzina, C.R., et al. 2003. Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ. Res. 92:159-168.
112. Papadatos, G.A., et al. 2002. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc. Natl. Acad. Sci. U. S. A. 99:6210-6215.
113. Priori, S.G., et al. 2004. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 292:1341-1344.
114. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 92:3381-3386.
115. Wang, D.W., Yazawa, K., Makita, N., George, A.L., Jr., and Bennett, P.B. 1997. Pharmacological targeting of long QT mutant sodium channels. J. Clin. Invest. 99:1714-1720.
116. Valdivia, C.R., et al. 2002. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc. Res. 55:279-289.
117. Windle, J.R., Geletka, R.C., Moss, A.J., Zareba, W., and Atkins, D.L. 2001. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann. Noninvasive Electrocardiol. 6:153-158.
118. Abriel, H., Wehrens, X.H., Benhorin, J., Kerem, B., and Kass, R.S. 2000. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation. 102:921-925.
119. Priori, S.G., et al. 2000. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 102:945-947.
120. Belhassen, B., Glick, A., and Viskin, S. 2004. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 110:1731-1737.
121. Glatter, K.A., et al. 2004. Effectiveness of sotalol treatment in symptomatic Brugada syndrome. Am. J. Cardiol. 93:1320-1322.
122. Macdonald, R.L., and Greenfield, L.J., Jr. 1997. Mechanisms of action of new antiepileptic drugs. Curr. Opin. Neurol. 10:121-128.
123. Catterall, W.A. 1999. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol. 79:441-456.
124. +-channel β1 subunit gene SCN1B. Nat. Genet 19:366-370.
125. Escayg, A., et al. 2000. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat. Genet. 24:343-345.
126. Claes, L., et al. 2001. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. 68:1327-1332.
127. v1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc. Natl. Acad. Sci. U. S. A. 98:6384-6389.
128. Fujiwara, T., et al. 2003. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain. 126:531-546.
129. Heron, S.E., et al. 2002. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet. 360:851-852.
130. A receptor dysfunction in epilepsy: a mutation in the γ2-subunit gene. Nat. Genet. 28:46-48.
131. A receptor γ2-subunit in childhood absence epilepsy and febrile seizures. Nat. Genet. 28:49-52.
132. Berkovic, S.F., et al. 2004. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann. Neurol. 55:550-557.
133. Ohmori, I., et al. 2003. Is phenotype difference in severe myoclonic epilepsy in infancy related to SCN1A mutations? Brain Dev. 25:488-493.
134. + channel α1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia. 45:140-148.
135. Escayg, A., et al. 2001. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus - and prevalence of variants in patients with epilepsy. Am. J. Hum. Genet. 68:866-873.
136. Wallace, R.H., et al. 2001. Neuronal sodium-channel α1-subunit mutations in generalized epilepsy with febrile seizures plus. Am. J. Hum. Genet. 68:859-865.
137. Abou-Khalil, B., et al. 2001. Partial epilepsy and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology. 57:2265-2272.
138. v1.1 mutations cause febrile seizures associated with afebrile partial seizures. Neurology. 57:703-705.
139. +-channel α1 subunit gene, SCN1A. Epilepsy Res. 48:15-23.
140. Ohmori, I., Ouchida, M., Ohtsuka, Y., Oka, E., and Shimizu, K. 2002. Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy. Biochem. Biophys. Res. Commun. 295:17-23.
141. Sugawara, T., et al. 2002. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology. 58:1122-1124.
142. Singh, R., et al. 2001. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+? Epilepsia. 42:837-844.
143. Audenaert, D., et al. 2003. A deletion in SCN1B is associated with febrile seizures and early-onset absence epilepsy. Neurology. 61:854-856.
144. + channels. J. Neurosci. 16:7117-7127.
145. + channel function in the extracellular domain of the β1 subunit. J. Biol. Chem. 273:3954-3962.
146. v1.2 currents and cell surface density is dependent on interactions with contactin and ankyrin. J. Biol. Chem. 279:16044-16049.
147. Meadows, L.S., et al. 2002. Functional and biochemical analysis of a sodium channel β1 subunit mutation responsible for generalized epilepsy with febrile seizures plus type 1. J. Neurosci. 22:10699-10709.
148. Chen, C., et al. 2004. Mice lacking sodium channel β1 subunits display defects in neuronal excitability, sodium channel expression, and nodal architecture J. Neurosci. 24:4030-4042.
149. Lossin, C., Wang, D.W., Rhodes, T.H., Vanoye, C.G., and George, A.L., Jr. 2002. Molecular basis of an inherited epilepsy. Neuron. 34:877-884.
150. Spampanato, J., et al. 2004. A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction. J. Neurosci. 24:10022-10034.
151. Lossin, C., et al. 2003. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J. Neurosci. 23:11289-11295.
152. Rhodes, T.H., Lossin, C., Vanoye, C.G., Wang, D.W., and George, A.L., Jr. 2004. Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy. Proc. Natl. Acad. Sci. U. S. A. 101:11147-11152.
153. Yang, Y., et al. 2004. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet. 41:171-174.
154. v1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 24:8232-8236.
155. Jang, H.S., et al. 2004. A case of primary erythromelalgia improved by mexiletine. Br. J. Dermatol. 151:708-710.
156. Legroux-Crespel, E., et al. 2003. Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Ann. Dermatol. Venereol. 130:429-433.
157. Stricker, L.J., and Green, C.R. 2001. Resolution of refractory symptoms of secondary erythermalgia with intermittent epidural bupivacaine. Reg. Anesth. Pain Med. 26:488-490.
158. v1.6 and a genetically linked retinal mutation, rd13. Mamm. Genome. 15:344-351.
159. Kohrman, D.C., Smith, M.R., Goldin, A.L., Harris, J., and Meisler, M.H. 1996. A missense mutation in the sodium channel Scn8a is responsible for cerebellar ataxia in the mouse mutant jolting. J. Neurosci. 16:5993-5999.
160. Chen, C., et al. 2002. Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel β2-subunits. Proc. Natl. Acad. Sci. U. S. A. 99:17072-17077.